ARGENX BV


Associated tags: Health, Development, Pharmaceutical industry, Safety, Upper respiratory tract infection, Cytokine, American Academy of Dermatology, LEO, AAD, Patient, MD, Dermatology, Atopic dermatitis, Clinical Trials, American Academy, COVID-19, Aes, BV, Leo Pharma, University

LEO Pharma Presents Late-Breaking Positive Phase 2a Efficacy and Safety Results of LEO 138559 in Moderate-to-Severe Atopic Dermatitis at the 2023 AAD Annual Meeting

Retrieved on: 
Saturday, March 18, 2023
Health, Clinical Trials, Research, Pharmaceutical, Science, Biotechnology, Conditional sentence, University, Leo Pharma, BV, Aes, COVID-19, American Academy, Atopic dermatitis, Development, Dermatology, MD, Patient, AAD, LEO, American Academy of Dermatology, Cytokine, Upper respiratory tract infection, Safety, Pharmaceutical industry, EASI

LEO Pharma A/S, a global leader in medical dermatology, today announced that a Phase 2a trial evaluating the efficacy and safety of investigational agent LEO 138559 in adults with moderate-to-severe atopic dermatitis met its primary endpoint.

Key Points: 
  • LEO Pharma A/S, a global leader in medical dermatology, today announced that a Phase 2a trial evaluating the efficacy and safety of investigational agent LEO 138559 in adults with moderate-to-severe atopic dermatitis met its primary endpoint.
  • Results were shared as one of two LEO Pharma late breaker oral presentations at the 2023 American Academy of Dermatology (AAD) Annual Meeting.1 LEO 138559 is an investigational agent and its efficacy and safety are subject to further larger trials.
  • LEO Pharma and argenx BV jointly developed LEO 138559 under an exclusive option and research agreement.
  • LEO Pharma obtained the license to LEO 138559 in 2022 and now assumes the responsibility to develop and commercialize LEO 138559 for inflammatory skin disorders, such as atopic dermatitis.